Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) on Friday, soared 4.82% from the previous trading day, before settling in for the closing price of $1.66. Within the past 52 weeks, ZNTL’s price has moved between $1.66 and $18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 44.78%. With a float of $55.11 million, this company’s outstanding shares have now reached $71.15 million.
Let’s look at the performance matrix of the company that is accounted for 168 employees. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zentalis Pharmaceuticals Inc is 22.67%, while institutional ownership is 81.37%. The most recent insider transaction that took place on Jan 02 ’25, was worth 13,762. In this transaction Chief Scientific Officer of this company sold 4,411 shares at a rate of $3.12, taking the stock ownership to the 191,317 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Former Chief Medical Officer proposed sale 9,888 for $2.86, making the entire transaction worth $28,294.
Zentalis Pharmaceuticals Inc (ZNTL) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.66% during the next five years compared to -50.05% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Zentalis Pharmaceuticals Inc (ZNTL) is currently performing well based on its current performance indicators. A quick ratio of 7.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.56 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) saw its 5-day average volume 5.32 million, a positive change from its year-to-date volume of 2.92 million. As of the previous 9 days, the stock’s Stochastic %D was 18.05%. Additionally, its Average True Range was 0.28.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 2.12%, which indicates a significant decrease from 6.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 142.87% in the past 14 days, which was higher than the 99.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.9528, while its 200-day Moving Average is $5.1692. Nevertheless, the first resistance level for the watch stands at $1.7900 in the near term. At $1.8400, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8900. If the price goes on to break the first support level at $1.6900, it is likely to go to the next support level at $1.6400. The third support level lies at $1.5900 if the price breaches the second support level.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
Market capitalization of the company is 124.00 million based on 71,265K outstanding shares. Right now, sales total 0 K and income totals -292,190 K. The company made 0 K in profit during its latest quarter, and -88,280 K in sales during its previous quarter.
